The British Journal of Cancer has published a paper about the Phase II trial of Merrimack Pharmaceuticals' (MACK +5.2%) MM-398 drug for treating late-stage pancreatic cancer.
The study met its primary endpoint, with 75% of patients surviving at least 3 months, including 25% who reached the one-year mark. The median overall survival was 5.2 months, while 50% of patients showed evidence of disease control.
MM-398 is now in Phase III trials. (PR)
Last week, SA author Ross Breckendridge noted that Merrimack's share price has been swinging significantly recently in response to interim clinical trial data from MM-121. Breckendridge believes that any downside "has been due to the misconception of the meaning of the data released, and a somewhat poor communication effort by the company."